Can Oscar Health Sustain Its Profit Rebound as Medical Costs Rise?

Oscar Health reported a sharp Q2 2026 turnaround, with revenue rising 70% year over year to $4.88B, membership increasing to 2.96M from 2.03M, and operating earnings reaching $388.6M versus a $230.5M loss a year earlier. Its medical loss ratio improved to 79.2% from 91.1%, and the company raised 2026 operating-earnings guidance to $600M-$800M while lowering its expected MLR to 81%-82%. However, $1.09B of first-half operating earnings implies a $293M-$493M second-half loss under the updated outlook as medical costs rise; OSCR shares are up 111.5% YTD but trade at 4.61x book value versus a 2.71x industry average.

Analysis

OSCR's key equity risk is not membership growth but earnings seasonality: the implied back-half underwriting giveback leaves little room for adverse reserve development, specialty-drug trend, or utilization intensity among newer enrollees. Because the stock has already rerated on the first-half margin surprise, each 100 bps miss versus the medical-cost target would likely matter more to valuation than another increment of membership growth. The next two quarterly reports are therefore a test of pricing adequacy and claims reserving, not of demand.

The non-obvious offset is ACA risk adjustment. Fast growth can improve fixed-cost absorption, but it can also change the morbidity mix and create a material payable if OSCR's new members prove healthier than the market; conversely, an adverse-risk cohort makes the reported low loss ratio less durable. Investors should monitor disclosed risk-adjustment accruals, prior-period development, and the gap between paid and incurred claims. A deterioration in any of those metrics would challenge the view that technology-led administrative efficiency is translating into structurally superior underwriting.

CNC is the cleaner relative beneficiary if investors rotate from growth-at-a-premium toward earnings quality: its diversified government-program exposure makes a single ACA utilization surprise less consequential. MOH has greater leverage to state-rate adequacy and Medicaid redetermination normalization, so it is less suitable as a direct OSCR hedge despite the cheaper valuation profile. Consensus appears to be extrapolating the favorable first-half loss ratio; the contrarian view is that the already implied second-half loss is not a temporary anomaly but the economic cost of retaining growth, which would cap long-run multiple expansion.

Key Decisions for Investors

• Initiate a 1-3 month relative-value position: short OSCR / long CNC, dollar-neutral. The trade targets a compression of OSCR's premium valuation if third-quarter medical-cost or reserve disclosures weaken; cover if OSCR reaffirms full-year operating earnings while reporting stable or improving incurred-claims trend and no increase in risk-adjustment liabilities.
• Do not add outright OSCR exposure ahead of the next earnings release without claims-reserve detail. Upgrade to a tactical long only if third-quarter results demonstrate medical-cost performance within guidance while the implied fourth-quarter loss narrows; that would validate that first-half margins were not simply favorable timing.
• For existing OSCR longs, buy downside protection through post-earnings dated put spreads rather than selling outright after the sharp rerating. The catalyst window is the next 30-90 days; a miss on medical loss ratio or adverse development can produce disproportionate downside because the valuation already assumes sustained underwriting credibility.
• Keep MOH on a separate watch list rather than using it as the primary hedge. Add only after visibility improves on Medicaid rate adequacy and membership stabilization; a further enrollment decline or unfavorable state-rate actions would falsify the defensive-quality thesis even if OSCR weakens.